{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:04:21Z","timestamp":1789416261181,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["204725-3"],"award-info":[{"award-number":["204725-3"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.cct.2023.107360","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:57:26Z","timestamp":1697691446000},"page":"107360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial"],"prefix":"10.1016","volume":"135","author":[{"given":"Arild","family":"Opheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117 \u0160altyt\u0117","family":"Benth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Klemmetsby","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia S.","family":"Kloster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Kun\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Gaulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.cct.2023.107360_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose\u2013effects and time-course","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2023.107360_bb0010","series-title":"\u2018Not at all what I had expected\u2019: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study","first-page":"108667","author":"Brenna","year":"2021"},{"issue":"8","key":"10.1016\/j.cct.2023.107360_bb0015","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: A systematic review of risk factors","volume":"33","author":"Brorson","year":"2013","journal-title":"Clin. Psychol. Rev."},{"issue":"4","key":"10.1016\/j.cct.2023.107360_bb0020","first-page":"313","article-title":"Transition of patients with opioid use disorder from Buprenorphine to extended-release naltrexone: a randomized clinical trial assessing two transition regimens","volume":"29","author":"Comer","year":"2020"},{"issue":"2","key":"10.1016\/j.cct.2023.107360_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2023.107360_bb0030","first-page":"56","article-title":"The predictive value of degree of preference for extended-release naltrexone for treatment adherence","volume":"28","author":"Gaulen","year":"2022","journal-title":"Opioid Use, Relapse."},{"issue":"4","key":"10.1016\/j.cct.2023.107360_bb0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/02791072.2021.1976887","article-title":"Predictors of relapse to alcohol and substance use: are there any differences between 3 and 12 months after inpatient treatment?","volume":"54","author":"Guliyev","year":"2022","journal-title":"J. Psychoactive Drugs"},{"issue":"9","key":"10.1016\/j.cct.2023.107360_bb0040","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.cct.2023.107360_bb0045","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1360-0443.2010.03031.x","article-title":"Challenges to antagonist blockade during sustained-release naltrexone treatment","volume":"105","author":"Kun\u00f8e","year":"2010","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.cct.2023.107360_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0061-1","article-title":"Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)","volume":"17","author":"Kun\u00f8e","year":"2016","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.cct.2023.107360_bb0055","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: A randomized clinical trial and follow-up study","author":"Latif","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"10118","key":"10.1016\/j.cct.2023.107360_bb0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2023.107360_bb0065","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/dar.13401","article-title":"Is the relapse concept in studies of substance use disorders a \u2018one size fits all\u2019concept? A systematic review of relapse operationalisations","volume":"41","author":"Moe","year":"2022","journal-title":"Drug. Alcohol. Rev."},{"key":"10.1016\/j.cct.2023.107360_bb0070","series-title":"The Drug Situation in Norway 2014 (Annual Report to the EMCDDA)","author":"Norwegian Institute for Alcohol and Drug Research","year":"2015"},{"key":"10.1016\/j.cct.2023.107360_bb0075","series-title":"Opioid Use and Dropout from Extended-Release Naltrexone in a Controlled Trial: Implications for Mechanism","author":"Nunes","year":"2019"},{"issue":"5","key":"10.1016\/j.cct.2023.107360_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/ajad.13151","article-title":"Risk of relapse among opioid-dependent patients treated with extended-release naltrexone or buprenorphine-naloxone: A randomized clinical trial","volume":"30","author":"Opheim","year":"2021","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.cct.2023.107360_bb0085","series-title":"Increases in Drug and opioid Overdose Deaths - United States, 2000\u20132014","author":"Rudd","year":"2016"},{"key":"10.1016\/j.cct.2023.107360_bb0090","series-title":"Timeline Follow-Back: a Technique for Assessing Self-Reported Alcohol Consumption","author":"Sobell","year":"1992"},{"issue":"6","key":"10.1016\/j.cct.2023.107360_bb0095","first-page":"303","article-title":"Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: extension of a randomized clinical","volume":"25","author":"Solli","year":"2019","journal-title":"Trial."},{"issue":"10","key":"10.1016\/j.cct.2023.107360_bb0100","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/add.14278","article-title":"Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a nine-month follow-up to a three-month randomized trial","volume":"113","author":"Solli","year":"2018","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.cct.2023.107360_bb0105","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/add.15378","article-title":"Adapting treatment length to opioid-dependent individuals\u2019 needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone","volume":"116","author":"Solli","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2023.107360_bb0110","article-title":"Opioid use disorder","author":"Strang","year":"2020","journal-title":"Nature 6, Article number: 3"},{"issue":"12","key":"10.1016\/j.cct.2023.107360_bb0115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2023.107360_bb0120","series-title":"World Drug Report 2015","author":"UNODC","year":"2015"},{"issue":"22","key":"10.1016\/j.cct.2023.107360_bb0125","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies--tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423002835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423002835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:00:37Z","timestamp":1761555637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714423002835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"alternative-id":["S1551714423002835"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107360","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107360"}}